Sec Form 4 Filing - Legorreta Pablo G. @ Royalty Pharma plc - 2023-05-12

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Legorreta Pablo G. 2. Issuer Name and Ticker or Trading Symbol Royalty Pharma plc [ RPRX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner X __ Officer (give title below) _____ Other (specify below) CEO, Chairman of the Board (Last) (First) (Middle) C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET 3. Date of Earliest Transaction (MM/DD/YY) 05/12/2023 (Street) NEW YORK, NY10022 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares ICAI Interests $ 0 05/12/2023 G( 1 ) 10,269 ( 2 ) ( 2 ) Limited Partnership interests in RPI US Partners 2019, LP ( 3 ) 10,269 $ 0 0 ( 4 ) I By Spouse ICAI Interests $ 0 05/12/2023 G( 1 ) 10,269 ( 2 ) ( 2 ) Limited Partnership interests in RPI US Partners 2019, LP ( 3 ) 10,269 $ 0 692,701 ( 4 ) D ICAI Interests $ 0 ( 2 ) ( 2 ) Limited Partnership interests in RPI US Partners 2019, LP ( 3 ) 1,007,488 1,007,488 ( 4 ) I By Legorreta Investments LLC

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Legorreta Pablo G. C/O ROYALTY PHARMA PLC 110 E. 59TH STREET NEW YORK, NY10022 X X CEO, Chairman of the Board Signatures /s/ Sean Weisberg, as Attorney-in-Fact for Pablo G. Legorreta 05/15/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Reflects an exempt gift for no consideration of ICAI Interests from the reporting person's spouse to the reporting person. ( 2 )These ICAI Interests represent a beneficial interest in an equivalent number of limited partnership interests ("RPI US LP Interests") in RPI US Partners 2019, LP ("RPI US LP") and may be exchanged into RPI US LP Interests on a one-for-one basis currently. The ICAI Interests do not have an expiration date. ( 3 )Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. ( 4 )Reflects the exempt change in the form of beneficial ownership without a change in the reporting person's pecuniary interest pursuant to Rule 16a-13 of certain ICAI Interests from being directly or indirectly owned by the reporting person through Legorreta Investments II LLC to being directly owned or indirectly owned through Legorreta Investments LLC and the reporting person's spouse.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.